mirtazapine has been researched along with Dementia in 11 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On cost-effectiveness grounds, the use of mirtazapine cannot be recommended for agitated behaviors in people living with dementia." | 9.51 | Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trial. ( Ballard, C; Banerjee, S; Bentham, P; Burns, A; Farina, N; Fountain, J; Fox, C; Francis, P; Henderson, C; High, J; Howard, R; Knapp, M; Leroi, I; Livingston, G; Nilforooshan, R; Nurock, S; O'Brien, JT; Price, A; Shepstone, L; Stirling, S; Swart, AM; Tabet, N; Telling, T; Thomas, AJ, 2022) |
| "This parallel-group, double-blind, placebo-controlled trial-the Study of Mirtazapine for Agitated Behaviours in Dementia trial (SYMBAD)-was done in 26 UK centres." | 9.41 | Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. ( Ballard, C; Banerjee, S; Bentham, P; Burns, A; Farina, N; Fox, C; Francis, P; Henderson, C; High, J; Howard, R; Knapp, M; Leroi, I; Livingston, G; Nilforooshan, R; Nurock, S; O'Brien, J; Price, A; Shepstone, L; Stirling, S; Swart, AM; Tabet, N; Telling, T; Thomas, AJ, 2021) |
| " Replication of the potential effects of mirtazapine in the subgroup of those with depression in dementia with "psychological" symptoms would be valuable." | 9.30 | Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial. ( Banerjee, S; Chua, KC; Hellier, J; Voshaar, RO; Zuidersma, M, 2019) |
| " (1) The secondary analyses presented here suggest that there would be value in carrying out a placebo-controlled trial of the clinical effectiveness and cost-effectiveness of mirtazapine in the management of Behavioural and Psychological Symptoms of Dementia." | 9.17 | Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Orrell, M; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| "To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo for depression in dementia." | 9.17 | Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| "On cost-effectiveness grounds, the use of mirtazapine cannot be recommended for agitated behaviors in people living with dementia." | 5.51 | Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trial. ( Ballard, C; Banerjee, S; Bentham, P; Burns, A; Farina, N; Fountain, J; Fox, C; Francis, P; Henderson, C; High, J; Howard, R; Knapp, M; Leroi, I; Livingston, G; Nilforooshan, R; Nurock, S; O'Brien, JT; Price, A; Shepstone, L; Stirling, S; Swart, AM; Tabet, N; Telling, T; Thomas, AJ, 2022) |
| "This parallel-group, double-blind, placebo-controlled trial-the Study of Mirtazapine for Agitated Behaviours in Dementia trial (SYMBAD)-was done in 26 UK centres." | 5.41 | Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. ( Ballard, C; Banerjee, S; Bentham, P; Burns, A; Farina, N; Fox, C; Francis, P; Henderson, C; High, J; Howard, R; Knapp, M; Leroi, I; Livingston, G; Nilforooshan, R; Nurock, S; O'Brien, J; Price, A; Shepstone, L; Stirling, S; Swart, AM; Tabet, N; Telling, T; Thomas, AJ, 2021) |
| " Replication of the potential effects of mirtazapine in the subgroup of those with depression in dementia with "psychological" symptoms would be valuable." | 5.30 | Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial. ( Banerjee, S; Chua, KC; Hellier, J; Voshaar, RO; Zuidersma, M, 2019) |
| " (1) The secondary analyses presented here suggest that there would be value in carrying out a placebo-controlled trial of the clinical effectiveness and cost-effectiveness of mirtazapine in the management of Behavioural and Psychological Symptoms of Dementia." | 5.17 | Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Orrell, M; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| "To evaluate the cost-effectiveness of sertraline and mirtazapine compared with placebo for depression in dementia." | 5.17 | Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. ( Baldwin, R; Ballard, C; Banerjee, S; Bentham, P; Burns, A; Dewey, M; Fox, C; Hellier, J; Holmes, C; Katona, C; Knapp, M; Lawton, C; Lindesay, J; Livingston, G; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, S; O'Brien, J; Poppe, M; Romeo, R; Thomas, A; Walwyn, R; Wilson, K, 2013) |
| "The prevalence of insomnia increases with age and affects up to 35% of community-dwelling adults with dementia." | 2.45 | Non-pharmacologic treatment of insomnia in persons with dementia. ( Darvishi, R; Kunik, ME; Shub, D, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 4 (36.36) | 2.80 |
| Authors | Studies |
|---|---|
| Lanctôt, KL | 1 |
| Herrmann, N | 1 |
| Banerjee, S | 6 |
| High, J | 2 |
| Stirling, S | 2 |
| Shepstone, L | 2 |
| Swart, AM | 2 |
| Telling, T | 2 |
| Henderson, C | 2 |
| Ballard, C | 5 |
| Bentham, P | 5 |
| Burns, A | 5 |
| Farina, N | 2 |
| Fox, C | 5 |
| Francis, P | 2 |
| Howard, R | 2 |
| Knapp, M | 5 |
| Leroi, I | 2 |
| Livingston, G | 5 |
| Nilforooshan, R | 2 |
| Nurock, S | 5 |
| O'Brien, J | 4 |
| Price, A | 2 |
| Thomas, AJ | 2 |
| Tabet, N | 2 |
| Fountain, J | 1 |
| O'Brien, JT | 1 |
| Zuidersma, M | 1 |
| Chua, KC | 1 |
| Hellier, J | 4 |
| Voshaar, RO | 1 |
| Almeida, OP | 1 |
| Romeo, R | 3 |
| Dewey, M | 3 |
| Baldwin, R | 3 |
| Holmes, C | 3 |
| Katona, C | 3 |
| Lawton, C | 3 |
| Lindesay, J | 3 |
| McCrae, N | 3 |
| Moniz-Cook, E | 3 |
| Murray, J | 3 |
| Orrell, M | 2 |
| Poppe, M | 3 |
| Thomas, A | 3 |
| Walwyn, R | 3 |
| Wilson, K | 3 |
| Shub, D | 1 |
| Darvishi, R | 1 |
| Kunik, ME | 1 |
| Brodaty, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pragmatic, Multi Centre, Double-blind, Placebo Controlled Randomised Trial to Assess the Safety, Clinical and Cost Effectiveness of Mirtazapine in Patients With Alzheimer's Disease (AD) and Agitated Behaviours[NCT03031184] | Phase 3 | 207 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mirtazapine and Dementia
| Article | Year |
|---|---|
Non-pharmacologic treatment of insomnia in persons with dementia.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antidepressive Agents, Tricyclic; Circadian Rhyth | 2009 |
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Do | 2011 |
7 trials available for mirtazapine and Dementia
| Article | Year |
|---|---|
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.
Topics: Aged, 80 and over; Anti-Anxiety Agents; Brief Psychiatric Rating Scale; Caregivers; Dementia; Double | 2021 |
No benefit from mirtazapine for treating agitation in dementia.
Topics: Dementia; Double-Blind Method; Humans; Mirtazapine | 2022 |
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trial.
Topics: Caregivers; Cost-Benefit Analysis; Dementia; Humans; Mirtazapine; Quality of Life | 2022 |
Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depression; Double-Blin | 2019 |
Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Dementia; Depr | 2013 |
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Do | 2011 |
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial.
Topics: Antidepressive Agents; Caregivers; Cost-Benefit Analysis; Dementia; Depression; Health Care Costs; H | 2013 |
3 other studies available for mirtazapine and Dementia
| Article | Year |
|---|---|
Mirtazapine for agitation in dementia: moving forward.
Topics: Antidepressive Agents; Dementia; Humans; Mianserin; Mirtazapine | 2021 |
The Challenge of Treating Depression in Dementia.
Topics: Dementia; Depression; Humans; Mirtazapine; Sertraline; Technology Assessment, Biomedical | 2019 |
Antidepressant treatment in Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Dementia; Depressive Disorder; Double-B | 2011 |